Loading...
XLONSNG
Market cap8mUSD
Dec 24, Last price  
2.56GBP
1D
1.99%
1Q
-34.02%
Jan 2017
-81.60%
Name

Synairgen PLC

Chart & Performance

D1W1MN
XLON:SNG chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
362.40%
Rev. gr., 5y
49.38%
Revenues
0k
82,000202,00082,00078,000000155,000004,2902505,02510500000
Net income
-8m
L-52.35%
-153,000-610,000-1,049,000-1,640,000-2,152,000-2,494,000-2,550,000-3,231,000-2,250,000-2,043,0001,188-2,255-2,817,0001,761-3,301-3,885,000-13,916,000-48,663,000-17,645,000-8,408,000
CFO
-8m
L-41.89%
-65,000-840,000-1,530,000-1,708,300-2,246,000-2,354,000-2,801,000-2,638,000-2,491,000-1,791,0001,803-1,933-2,9882,067-3,823-2,870,000-23,788,000-41,004,000-14,146,000-8,220,000
Earnings
Jun 25, 2025

Profile

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
URL
https://www.synairgen.com/
IPO date
Oct 26, 2004
Employees
30
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
10,376
20,300
57,866
Unusual Expense (Income)
NOPBT
(10,376)
(20,300)
(57,866)
NOPBT Margin
Operating Taxes
(1,249)
(2,448)
(9,194)
Tax Rate
NOPAT
(9,127)
(17,852)
(48,672)
Net income
(8,408)
-52.35%
(17,645)
-63.74%
(48,663)
249.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,000
14
BB yield
0.00%
0.00%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(12,016)
(19,676)
(33,827)
Cash flow
Cash from operating activities
(8,220)
(14,146)
(41,004)
CAPEX
(13)
(6)
(33)
Cash from investing activities
2,810
(3,756)
(33)
Cash from financing activities
1,000
(112)
FCF
(9,295)
(15,283)
(41,530)
Balance
Cash
12,016
19,676
33,827
Long term investments
Excess cash
12,016
19,676
33,827
Stockholders' equity
(113,071)
(104,970)
(88,245)
Invested Capital
125,728
125,039
124,835
ROIC
ROCE
EV
Common stock shares outstanding
201,375
201,360
200,442
Price
0.06
-55.70%
0.14
-93.51%
2.08
35.95%
Market cap
12,042
-55.70%
27,184
-93.48%
416,919
85.22%
EV
26
7,508
383,092
EBITDA
(10,292)
(20,198)
(57,671)
EV/EBITDA
Interest
2
Interest/NOPBT